C1516031||Anti-tumor activity
C4278992||SL4
C1512505||breast cancer cells
C1517345||G2/M arrest
C0752312||MAPK
C0288472||p21
C0037083||signaling pathway
C4278992||SL4
C0007935||chalcone
C1706082||compound
C1269955||tumor invasion
C1519670||angiogenesis
C0215848||HIF1
C0162638||apoptosis
C0162772||ROS
C0684224||report
C4278992||SL4
C0596290||proliferation
C1512505||breast cancer cell
C1515655||in vivo
C1517345||G2/M cell cycle arrest
C4278992||SL4
C0003392||anti-proliferative
C0086418||human
C0678222||breast cancer
C0085983||cell lines
C2603343||studies
C1444656||indicated
C4278992||SL4
C1517345||G2/M arrest
C0085983||cell lines
C4278992||SL4
C0017262||expression
C0297674||cyclin A2
C0213045||cdc25C
C0080054||cdc2
C0385333||cyclin B1
C1704241||complex
C4278992||SL4
C1533734||treatment
C0249197||p21
C0035696||mRNA
C0033684||protein
C2259058||activation
C1518102||MAPK signaling pathways
C1155363||TGF-Î² pathway
C0968383||SP600125
C0298346||PD98059
C0243077||inhibitors
C0291988||JNK kinase
C0600388||ERK kinase
C4278992||SL4
C1517345||G2/M phase arrest
C0041904||upregulation
C0288472||p21
C4278992||SL4
C0007595||growth
C1458155||breast tumors
C0025932||nude mice
C0041904||upregulation
C0288472||p21
C0013081||downregulation
C0213045||cdc25C
C0243095||findings
C4278992||SL4
C0003392||multi-target anti-tumor drug candidate